Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uma Sinha

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Blood|September 2, 2011
Critical role for Syk in responses to vascular injuryPatrick Andre, Toshifumi Morooka, Derek Sim, et al.
Bioorganic & Medicinal Chemistry Letters|July 1, 2004
Parallel synthesis and structure-activity relationships of a series of highly potent, selective, and neutral factor Xa inhibitorsShawn M Bauer, Erick A Goldman, Wenrong Huang, et al.
Journal of the American College of Cardiology|March 20, 2019
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid CardiomyopathyDaniel P Judge, Stephen B Heitner, Rodney H Falk, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2003
Design, synthesis and structure-activity relationships of benzoxazinone-based factor Xa inhibitorsWenrong Huang, Penglie Zhang, Jingmei F Zuckett, et al.
Bioorganic & Medicinal Chemistry Letters|April 15, 2004
N,N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as potent factor Xa inhibitorsZhaozhong J Jia, Ting Su, Jingmei F Zuckett, et al.
Bioorganic & Medicinal Chemistry Letters|May 29, 2002
Design, synthesis, and SAR of substituted acrylamides as factor Xa inhibitorsYonghong Song, Lane Clizbe, Chhaya Bhakta, et al.
The New England Journal of Medicine|January 10, 2024
Efficacy and Safety of Acoramidis in Transthyretin Amyloid CardiomyopathyJulian D Gillmore, Daniel P Judge, Francesco Cappelli, et al.
Journal of Cardiac Failure|May 13, 2026
Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM TrialAmrut V Ambardekar, Nitasha Sarswat, Richard Wright, et al.
Journal of the American College of Cardiology|May 21, 2025
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid CardiomyopathyMathew S Maurer, Daniel P Judge, Julian D Gillmore, et al.
Future Cardiology|December 12, 2025
A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathyJulian D Gillmore, Daniel P Judge, Francesco Cappelli, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Blood|September 2, 2011
Critical role for Syk in responses to vascular injuryPatrick Andre, Toshifumi Morooka, Derek Sim, et al.
Bioorganic & Medicinal Chemistry Letters|July 1, 2004
Parallel synthesis and structure-activity relationships of a series of highly potent, selective, and neutral factor Xa inhibitorsShawn M Bauer, Erick A Goldman, Wenrong Huang, et al.
Journal of the American College of Cardiology|March 20, 2019
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid CardiomyopathyDaniel P Judge, Stephen B Heitner, Rodney H Falk, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2003
Design, synthesis and structure-activity relationships of benzoxazinone-based factor Xa inhibitorsWenrong Huang, Penglie Zhang, Jingmei F Zuckett, et al.
Bioorganic & Medicinal Chemistry Letters|April 15, 2004
N,N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as potent factor Xa inhibitorsZhaozhong J Jia, Ting Su, Jingmei F Zuckett, et al.
Bioorganic & Medicinal Chemistry Letters|May 29, 2002
Design, synthesis, and SAR of substituted acrylamides as factor Xa inhibitorsYonghong Song, Lane Clizbe, Chhaya Bhakta, et al.
The New England Journal of Medicine|January 10, 2024
Efficacy and Safety of Acoramidis in Transthyretin Amyloid CardiomyopathyJulian D Gillmore, Daniel P Judge, Francesco Cappelli, et al.
Journal of Cardiac Failure|May 13, 2026
Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM TrialAmrut V Ambardekar, Nitasha Sarswat, Richard Wright, et al.
Journal of the American College of Cardiology|May 21, 2025
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid CardiomyopathyMathew S Maurer, Daniel P Judge, Julian D Gillmore, et al.
Future Cardiology|December 12, 2025
A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathyJulian D Gillmore, Daniel P Judge, Francesco Cappelli, et al.
Pageof 8